News | May 01, 2023
IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Subscribe To Our Newsletter & Stay Updated
